{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-193453","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2023-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.788635+00:00","generated_at":"2026-06-13T03:10:12.421529+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"UroGen appoints James A. Robinson Jr. to Board, increasing size to 9 directors","bullets":["Board increased from 8 to 9; Robinson appointed to fill vacancy and serve on Compliance Committee.","Initial option grant of 20,000 ordinary shares, vesting quarterly over 12 quarters.","Annual retainer of $40,000 plus $5,000 for Compliance Committee service.","Eligible for annual option grant of 10,000 shares at each annual shareholder meeting.","Standard indemnity agreement will be entered with Robinson."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-193453","json":"https://secwatch.observer/filing/0001193125-23-193453.json","markdown":"https://secwatch.observer/filing/0001193125-23-193453.md","text":"https://secwatch.observer/filing/0001193125-23-193453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/0001193125-23-193453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/d480915d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T03:10:12.421529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ded19827c","claim":"James A. Robinson Jr. was appointed as Director at UroGen Pharma Ltd..","evidence_excerpt":"appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/0001193125-23-193453-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}